Does Gilead offer "Summer Fridays?"

[Anonymous]

I work for a small biotech and I'm petitioning for "Summer Fridays." This would be half-days every Friday from Memorial Day to Labor Day. I need to compile a list of benefits offered at bigger biotechs. Does Gilead offer anything like this? What do other companies offer?

 

[Anonymous]

I work for a small biotech and I'm petitioning for "Summer Fridays." This would be half-days every Friday from Memorial Day to Labor Day. I need to compile a list of benefits offered at bigger biotechs. Does Gilead offer anything like this? What do other companies offer?

I've been taking "Summer Fridays" every week for the last decade or so. Didn't realize there was a name for it...must be ahead of a trend here!

 

[Anonymous]

The HIV division works on an abbreviated schedule.
Tues-Thurs, 10-2

 

[Anonymous]

The HIV division works on an abbreviated schedule.
Tues-Thurs, 10-2

PAH and IHD don't work period. Have you seen the balance sheet from the last earnings report?

 

[Anonymous]

PAH and IHD don't work period. Have you seen the balance sheet from the last earnings report?

Yes stock dip after qtrly earnings seemed to be related to lack luster performance in antiviral! It did not seem to be related to IHD/PAH!

Just remember Antiviral. We in PAH/IHD are counting on you to raise the stock price so our ESOP/RSU/stock options are worth millions, then we can retire on our ill gotten gains!!

Pull the cart faster antiviral we dont have all day!

 

[Anonymous]

Yes stock dip after qtrly earnings seemed to be related to lack luster performance in antiviral! It did not seem to be related to IHD/PAH!

Just remember Antiviral. We in PAH/IHD are counting on you to raise the stock price so our ESOP/RSU/stock options are worth millions, then we can retire on our ill gotten gains!!

Pull the cart faster antiviral we dont have all day!

Get off your lazy ass and sell something.

 

[Anonymous]

Yes stock dip after qtrly earnings seemed to be related to lack luster performance in antiviral! It did not seem to be related to IHD/PAH!

Just remember Antiviral. We in PAH/IHD are counting on you to raise the stock price so our ESOP/RSU/stock options are worth millions, then we can retire on our ill gotten gains!!

Pull the cart faster antiviral we dont have all day!

Funny, nothing in the quarterly earnings is ever related to IHD/PAH.

 

[Anonymous]

Funny, nothing in the quarterly earnings is ever related to IHD/PAH.

PRESS RELEASES
PRESS RELEASE ARCHIVE
MEDIA INQUIRIES
POLICY PERSPECTIVES
MEDIA FAQ
Press Release Archive
Visit the Gilead News Release Archive

Gilead Sciences Announces First Quarter 2011 Financial Results
- Product Sales of $1.86 Billion, Up 4 Percent over First Quarter 2010 -
- Antiviral Product Sales of $1.63 Billion, Up 2 Percent over First Quarter 2010 -
- Reiterates Full Year 2011 Guidance -
FOSTER CITY, Calif., Apr 20, 2011 (BUSINESS WIRE) --

Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended March 31, 2011. Total revenues for the first quarter of 2011 were $1.93 billion, down 8 percent compared to total revenues of $2.09 billion for the first quarter of 2010. Net income for the first quarter of 2011 was $651.1 million, or $0.80 per diluted share, compared to net income for the first quarter of 2010 of $854.9 million, or $0.92 per diluted share. Non-GAAP net income for the first quarter of 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $702.8 million, or $0.87 per diluted share, compared to non-GAAP net income for the first quarter of 2010 of $914.8 million, or $0.99 per diluted share. Total revenues, GAAP and non-GAAP net income and diluted earnings per share decreased for the first quarter of 2011 due primarily to a $235.2 million or 95 percent decrease in Tamiflu(R) (oseltamivir phosphate) royalties resulting from a decline in pandemic planning initiatives worldwide.

Product Sales

Product sales increased 4 percent to $1.86 billion for the first quarter of 2011, compared to $1.79 billion in the first quarter of 2010, inclusive of the net price reductions taken in the United States due to healthcare reform and due to austerity measures in certain countries of Europe.

Antiviral Franchise

Antiviral product sales increased 2 percent to $1.63 billion in the first quarter of 2011, up from $1.60 billion for the same quarter of 2010, driven primarily by sales volume growth in the United States and Europe. Sequentially, antiviral product sales decreased 4 percent from $1.70 billion for the previous quarter, due primarily to declines in wholesaler inventory within the contractual boundaries set by Gilead's inventory management agreements and lower levels of purchasing by certain AIDS Drug Assistance Program (ADAP) entities.

Atripla
Sales of Atripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection increased 7 percent to $744.5 million for the first quarter of 2011, up from $692.9 million in the first quarter of 2010, driven primarily by sales volume growth in the United States and Europe.

Truvada
Sales of Truvada(R) (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection increased 2 percent to $673.1 million for the first quarter of 2011, up from $657.8 million in the first quarter of 2010, driven primarily by sales volume growth in the United States, Europe and Latin America.

Viread
Sales of Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B decreased 7 percent to $168.4 million for the first quarter of 2011, down from $180.7 million in the first quarter of 2010, due primarily to decreased sales volume in Brazil.

Letairis

Sales of Letairis(R) (ambrisentan) for the treatment of pulmonary arterial hypertension increased 12 percent to $62.2 million for the first quarter of 2011, up from $55.5 million for the first quarter of 2010, driven primarily by sales volume growth.

Ranexa

Sales of Ranexa(R) (ranolazine) for the treatment of chronic angina increased 33 percent to $68.3 million for the first quarter of 2011, up from $51.2 million for the first quarter of 2010, driven primarily by sales volume grow



Funny you prob just missed it!

 

[Anonymous]

Funny, nothing in the quarterly earnings is ever related to IHD/PAH.

you might have justed missed it.

PRESS RELEASES
PRESS RELEASE ARCHIVE
MEDIA INQUIRIES
POLICY PERSPECTIVES
MEDIA FAQ
Press Release Archive
Visit the Gilead News Release Archive

Gilead Sciences Announces First Quarter 2011 Financial Results
- Product Sales of $1.86 Billion, Up 4 Percent over First Quarter 2010 -
- Antiviral Product Sales of $1.63 Billion, Up 2 Percent over First Quarter 2010 -
- Reiterates Full Year 2011 Guidance -
FOSTER CITY, Calif., Apr 20, 2011 (BUSINESS WIRE) --

Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended March 31, 2011. Total revenues for the first quarter of 2011 were $1.93 billion, down 8 percent compared to total revenues of $2.09 billion for the first quarter of 2010. Net income for the first quarter of 2011 was $651.1 million, or $0.80 per diluted share, compared to net income for the first quarter of 2010 of $854.9 million, or $0.92 per diluted share. Non-GAAP net income for the first quarter of 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $702.8 million, or $0.87 per diluted share, compared to non-GAAP net income for the first quarter of 2010 of $914.8 million, or $0.99 per diluted share. Total revenues, GAAP and non-GAAP net income and diluted earnings per share decreased for the first quarter of 2011 due primarily to a $235.2 million or 95 percent decrease in Tamiflu(R) (oseltamivir phosphate) royalties resulting from a decline in pandemic planning initiatives worldwide.

Product Sales

Product sales increased 4 percent to $1.86 billion for the first quarter of 2011, compared to $1.79 billion in the first quarter of 2010, inclusive of the net price reductions taken in the United States due to healthcare reform and due to austerity measures in certain countries of Europe.

Antiviral Franchise

Antiviral product sales increased 2 percent to $1.63 billion in the first quarter of 2011, up from $1.60 billion for the same quarter of 2010, driven primarily by sales volume growth in the United States and Europe. Sequentially, antiviral product sales decreased 4 percent from $1.70 billion for the previous quarter, due primarily to declines in wholesaler inventory within the contractual boundaries set by Gilead's inventory management agreements and lower levels of purchasing by certain AIDS Drug Assistance Program (ADAP) entities.

Atripla
Sales of Atripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection increased 7 percent to $744.5 million for the first quarter of 2011, up from $692.9 million in the first quarter of 2010, driven primarily by sales volume growth in the United States and Europe.

Truvada
Sales of Truvada(R) (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection increased 2 percent to $673.1 million for the first quarter of 2011, up from $657.8 million in the first quarter of 2010, driven primarily by sales volume growth in the United States, Europe and Latin America.

Viread
Sales of Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B decreased 7 percent to $168.4 million for the first quarter of 2011, down from $180.7 million in the first quarter of 2010, due primarily to decreased sales volume in Brazil.

Letairis

Sales of Letairis(R) (ambrisentan) for the treatment of pulmonary arterial hypertension increased 12 percent to $62.2 million for the first quarter of 2011, up from $55.5 million for the first quarter of 2010, driven primarily by sales volume growth.

Ranexa

Sales of Ranexa(R) (ranolazine) for the treatment of chronic angina increased 33 percent to $68.3 million for the first quarter of 2011, up from $51.2 million for the first quarter of 2010, driven primarily by sales volume grow

 

[Anonymous]

you might have justed missed it.

PRESS RELEASES
PRESS RELEASE ARCHIVE
MEDIA INQUIRIES
POLICY PERSPECTIVES
MEDIA FAQ
Press Release Archive
Visit the Gilead News Release Archive

Gilead Sciences Announces First Quarter 2011 Financial Results
- Product Sales of $1.86 Billion, Up 4 Percent over First Quarter 2010 -
- Antiviral Product Sales of $1.63 Billion, Up 2 Percent over First Quarter 2010 -
- Reiterates Full Year 2011 Guidance -
FOSTER CITY, Calif., Apr 20, 2011 (BUSINESS WIRE) --

Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended March 31, 2011. Total revenues for the first quarter of 2011 were $1.93 billion, down 8 percent compared to total revenues of $2.09 billion for the first quarter of 2010. Net income for the first quarter of 2011 was $651.1 million, or $0.80 per diluted share, compared to net income for the first quarter of 2010 of $854.9 million, or $0.92 per diluted share. Non-GAAP net income for the first quarter of 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $702.8 million, or $0.87 per diluted share, compared to non-GAAP net income for the first quarter of 2010 of $914.8 million, or $0.99 per diluted share. Total revenues, GAAP and non-GAAP net income and diluted earnings per share decreased for the first quarter of 2011 due primarily to a $235.2 million or 95 percent decrease in Tamiflu(R) (oseltamivir phosphate) royalties resulting from a decline in pandemic planning initiatives worldwide.

Product Sales

Product sales increased 4 percent to $1.86 billion for the first quarter of 2011, compared to $1.79 billion in the first quarter of 2010, inclusive of the net price reductions taken in the United States due to healthcare reform and due to austerity measures in certain countries of Europe.

Antiviral Franchise

Antiviral product sales increased 2 percent to $1.63 billion in the first quarter of 2011, up from $1.60 billion for the same quarter of 2010, driven primarily by sales volume growth in the United States and Europe. Sequentially, antiviral product sales decreased 4 percent from $1.70 billion for the previous quarter, due primarily to declines in wholesaler inventory within the contractual boundaries set by Gilead's inventory management agreements and lower levels of purchasing by certain AIDS Drug Assistance Program (ADAP) entities.

Atripla
Sales of Atripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection increased 7 percent to $744.5 million for the first quarter of 2011, up from $692.9 million in the first quarter of 2010, driven primarily by sales volume growth in the United States and Europe.

Truvada
Sales of Truvada(R) (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection increased 2 percent to $673.1 million for the first quarter of 2011, up from $657.8 million in the first quarter of 2010, driven primarily by sales volume growth in the United States, Europe and Latin America.

Viread
Sales of Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B decreased 7 percent to $168.4 million for the first quarter of 2011, down from $180.7 million in the first quarter of 2010, due primarily to decreased sales volume in Brazil.

Letairis

Sales of Letairis(R) (ambrisentan) for the treatment of pulmonary arterial hypertension increased 12 percent to $62.2 million for the first quarter of 2011, up from $55.5 million for the first quarter of 2010, driven primarily by sales volume growth.

Ranexa

Sales of Ranexa(R) (ranolazine) for the treatment of chronic angina increased 33 percent to $68.3 million for the first quarter of 2011, up from $51.2 million for the first quarter of 2010, driven primarily by sales volume grow

All that cutting and pasting for that?
Really? ~$120 million vs $1.87 BILLION ...

REALLY?

Idiot

 

[Anonymous]

ohhhh HIV is so tough!!! We're on all the guidelines so its difficult to sell physicians on using our products. I have to work so hard, blah blah blah.....keep making us money and quite down

 

[Anonymous]

ohhhh HIV is so tough!!! We're on all the guidelines so its difficult to sell physicians on using our products. I have to work so hard, blah blah blah.....keep making us money and quite down

Open your eyes, idiot, and shut your mouth. You are coming across as a fool, but then again, you have been told this many times before.

 

[Anonymous]

I work for a small biotech and I'm petitioning for "Summer Fridays." This would be half-days every Friday from Memorial Day to Labor Day. I need to compile a list of benefits offered at bigger biotechs. Does Gilead offer anything like this? What do other companies offer?

LOL... good one... the answer is yes except on days that end with "Y".

 

[Anonymous]

Shoot, summer fridays?? That would be nice. I work saturday and sunday too

 

[Anonymous]

The HIV division works on an abbreviated schedule.
Tues-Thurs, 10-2

You forgot to say the other three days are optional work days. HIV sales is a scam.